ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2520

Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis

Carmen Lasa1, Raul Fernandez-Ramon2, Jorge Javier Gaitán2, Jose Luis Martin-Varillas3, Rosalía Demetrio2, Ivan Ferraz Amaro4, Santos Castañeda5 and Ricardo Blanco6, 1Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, 2Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3Hospital de Laredo, Laredo, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Hospital de la Princesa, Madrid, Spain, 6Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

Meeting: ACR Convergence 2023

Keywords: Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

Session Type: Abstract Session

Session Time: 4:00PM-5:30PM

Background/Purpose: Sarcoidosis is a disease with heterogeneous clinical presentation and course. The objective of this study is the identification of clinical phenotypes using cluster analysis.

Methods: A model-based clustering relaying on 19 clinical variables was performed in a retrospective cohort of 342 sarcoidosis patients, diagnosed and follow-up from 1999 to 2019 in a hospital at Northern Spain. Chi-square test and ANOVA were used to compare categorical and continuous variables among groups. Two-sample t-tests and the partition of Pearson’s chi-square statistic were used in pairwise comparisons. The Wasfi severity score was calculated and compared among clusters.

Results: Cluster analysis identified five groups: C1: erythema nodosum and articular involvement (n=55; 16.1%), C2: miscellaneous extrapulmonary sarcoidosis (n=49; 14.3%), C3: ocular and/or neurological involvement (n=83; 24.3%), C4: isolated hiliar adenopathy (n=17; 5.0%), and C5: parenchymal lung involvement with dyspnea (n=138; 40.4%). Lung involvement was predominant in all clusters, ranging from 89.9% (C5) to 100% (C1 and C4), except for C2 (55.1%). Extrapulmonary involvement was significantly higher in C2 (96.4%) and C3 (98.0%). Demographic and clinical characteristics are shown in Table 1. A significant low mean FEV1 was detected in C5 (90.5±21.8) versus C1 (102.0±22.9), C3 (102.3±17.6) and C4 (105.8±20.8). The cluster 5 had a significantly lower mean FVC (96.6±18.9) than the other clusters, ranging from 108.1±18.0 (C3) to 111.5±21.7 (C4). The prescription of systemic steroids and non-corticosteroid immunosuppressants was significantly higher in the clusters 1, 3 and 5. Chronicity rates were significantly higher in C3 (31.3%) and C5 (32.6%) compared to C1 (9.1%) and C4 (0%). The clusters 3 and 5 also showed significantly higher severity score values. According to the clusters identified in the present study, we proposed an individualized “treat to target” schedule by subgroups (Figure 1).

Conclusion: Five phenotypes of sarcoidosis with different clinical and prognostic characteristics are proposed in our study. Cluster analysis can be a useful tool for identifying clinical patterns in a disease as heterogeneous as sarcoidosis and facilitating its management.

Supporting image 1

Supporting image 2


Disclosures: C. Lasa: None; R. Fernandez-Ramon: None; J. Gaitán: None; J. Martin-Varillas: None; R. Demetrio: None; I. Ferraz Amaro: AbbVie/Abbott, 5, 6, Amgen, 5, 6, Bristol-Myers Squibb(BMS), 6; S. Castañeda: None; R. Blanco: AbbVie, 5, 6, Amgen, 6, AstraZeneca, 2, BMS, 6, Eli Lilly, 6, Galapagos, 2, 6, Janssen, 2, 6, MSD, 6, Novartis, 2, 6, Pfizer, 2, 6, Roche, 5, 6, Sanofi, 6.

To cite this abstract in AMA style:

Lasa C, Fernandez-Ramon R, Gaitán J, Martin-Varillas J, Demetrio R, Ferraz Amaro I, Castañeda S, Blanco R. Identification of Clinical Phenotypes in Sarcoidosis Using a Cluster Analysis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/identification-of-clinical-phenotypes-in-sarcoidosis-using-a-cluster-analysis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-clinical-phenotypes-in-sarcoidosis-using-a-cluster-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology